CN1104209A - 2，4-二氨基-3-羟基羧酸衍生物 - Google Patents

2，4-二氨基-3-羟基羧酸衍生物 Download PDF

Info

Publication number
CN1104209A
CN1104209A CN94102292A CN94102292A CN1104209A CN 1104209 A CN1104209 A CN 1104209A CN 94102292 A CN94102292 A CN 94102292A CN 94102292 A CN94102292 A CN 94102292A CN 1104209 A CN1104209 A CN 1104209A
Authority
CN
China
Prior art keywords
formula
compound
expression
methyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94102292A
Other languages
English (en)
Chinese (zh)
Inventor
A·比利希
B·夏皮奥特
P·艾特迈耶
H·格斯塔哈
P·李尔
D·索尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939305144A external-priority patent/GB9305144D0/en
Priority claimed from GB939319667A external-priority patent/GB9319667D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of CN1104209A publication Critical patent/CN1104209A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN94102292A 1993-03-12 1994-03-11 2，4-二氨基-3-羟基羧酸衍生物 Pending CN1104209A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9305144.9 1993-03-12
GB939305144A GB9305144D0 (en) 1993-03-12 1993-03-12 Organic compounds
GB939319667A GB9319667D0 (en) 1993-09-23 1993-09-23 Organic compounds
GB9319667.3 1993-09-23

Publications (1)

Publication Number Publication Date
CN1104209A true CN1104209A (zh) 1995-06-28

Family

ID=26302578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94102292A Pending CN1104209A (zh) 1993-03-12 1994-03-11 2，4-二氨基-3-羟基羧酸衍生物

Country Status (16)

Country Link
US (1) US5538997A (enExample)
EP (1) EP0615969A1 (enExample)
JP (1) JP3987586B2 (enExample)
KR (1) KR940021515A (enExample)
CN (1) CN1104209A (enExample)
AU (1) AU672867B2 (enExample)
CA (1) CA2118876A1 (enExample)
CZ (1) CZ55394A3 (enExample)
FI (1) FI941149L (enExample)
HU (1) HUT71793A (enExample)
IL (1) IL108930A0 (enExample)
NO (1) NO940844L (enExample)
NZ (1) NZ260063A (enExample)
PE (1) PE15695A1 (enExample)
SK (1) SK30394A3 (enExample)
TW (1) TW260662B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100357267C (zh) * 1999-04-27 2007-12-26 诺瓦提斯公司 2,4－二氨基－3－羟基羧酸衍生物在制备作为蛋白酶体抑制剂的药物中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
ATE218538T1 (de) * 1995-11-21 2002-06-15 Novartis Erfind Verwalt Gmbh Azahexan-derivate als substratisostere von retroviralen aspartat-proteasen
GB0012795D0 (en) * 2000-05-25 2000-07-19 Novartis Ag Organic compounds
CA2432908A1 (en) * 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Company Diamines as modulators of chemokine receptor activity
CA2453447A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2052892A1 (en) * 1990-10-11 1992-04-12 Suresh K. Balani Inhibitors of hiv protease
CA2109326A1 (en) * 1991-07-02 1993-01-03 Andreas Billich 4-amino-3-hydroxycarboxylic acid derivatives
GB9210744D0 (en) * 1992-05-20 1992-07-08 Pfizer Ltd Antiviral peptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100357267C (zh) * 1999-04-27 2007-12-26 诺瓦提斯公司 2,4－二氨基－3－羟基羧酸衍生物在制备作为蛋白酶体抑制剂的药物中的用途

Also Published As

Publication number Publication date
KR940021515A (ko) 1994-10-19
FI941149A7 (fi) 1994-12-22
NO940844L (no) 1994-09-13
TW260662B (enExample) 1995-10-21
IL108930A0 (en) 1994-06-24
HU9400745D0 (en) 1994-06-28
AU5773794A (en) 1994-09-15
HUT71793A (en) 1996-02-28
PE15695A1 (es) 1995-06-13
JP3987586B2 (ja) 2007-10-10
EP0615969A1 (en) 1994-09-21
CA2118876A1 (en) 1994-09-13
FI941149A0 (fi) 1994-03-10
FI941149L (fi) 1994-12-22
NZ260063A (en) 1996-02-27
CZ55394A3 (en) 1995-04-12
US5538997A (en) 1996-07-23
AU672867B2 (en) 1996-10-17
JPH0789919A (ja) 1995-04-04
NO940844D0 (no) 1994-03-10
SK30394A3 (en) 1995-03-08

Similar Documents

Publication Publication Date Title
CN1274288A (zh) 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
JP3798337B2 (ja) 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物
CN1426395A (zh) 二肽基肽酶iv抑制剂
CN1056141C (zh) 哌嗪衍生物
CN1309711C (zh) 3－酰氨基－1,2－苯并异噁唑衍生物、其制备方法及应用
CN1520293A (zh) 作为抗糖尿病药物的3-氟-吡咯烷类
CN1575171A (zh) 新型抗糖尿病剂
CZ211596A3 (cs) Inhibitory metaloproteázy, způsob jejich výroby, jejich použití a farmaceutické prostředky s jejich obsahem
CN1176080C (zh) 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途
CN1274283A (zh) 含喹啉的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1406234A (zh) 在2－位携带具有磺酰胺结构或砜结构的取代基的8,8a－二氢茚并[1,2－d]噻唑衍生物、它们的制备方法和它们作为药物的用途
CN1104209A (zh) 2，4-二氨基-3-羟基羧酸衍生物
CN1294578A (zh) 新的萘基和酰苯胺取代的磺酰胺
CN1216537A (zh) 具有生长激素释放特性的化合物
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
CN116018337A (zh) 铜绿假单胞菌毒力因子LasB抑制剂
CN1255131A (zh) 作为氧化氮合酶抑制剂的脒衍生物
JPWO2005056541A1 (ja) α−アミノ酸誘導体及びその医薬用途
HK1047281A1 (zh) 噻唑衍生物
CN1378538A (zh) 二氮芳辛－二酮衍生物及其作为类胰蛋白酶抑制剂的应用
CN1039017A (zh) 新化合物的制备方法
CN1102583C (zh) 噻唑正离子型多肽缩合剂、合成及其应用
CN1209352C (zh) 肼衍生物
CN1125444A (zh) 新型的二氮杂萘衍生物，它们的制备方法和含有它们的尤其用作抗增生药的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication